A method for synthesizing optically pure α-amino acid compounds
Optically pure α-amino acids can be synthesized through a two-step reaction of α-halogenated geminiboron compounds and chiral imines. This method solves the problems of harsh reaction conditions and low enantioselectivity in the synthesis of chiral α-amino acids in existing technologies, and realizes an efficient, green, and readily available synthetic method suitable for industrial production.
Patent Information
- Application Number
- CN202510617839.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies for synthesizing chiral α-amino acids suffer from problems such as harsh reaction conditions, low enantioselectivity, poor enzyme stability, and cumbersome synthesis of chiral catalysts, which limit their application scope and efficiency.
Optically pure α-amino acid compounds were synthesized by a two-step reaction involving α-halogenated geminiboron compounds and chiral imines under specific alkaline and temperature conditions, through geminiboron substitution and oxidation reactions.
This method achieves a highly efficient synthesis method that is simple to operate, uses readily available raw materials, operates under mild conditions, and is environmentally friendly. The products are easy to separate and purify, and it is suitable for synthesizing various functionalized chiral α-amino acids. It is particularly suitable for large-scale industrial production, with a yield of up to 95% and a diastereomer ratio greater than 50:1.
Smart Images

Figure CN123106489A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of organic chemistry technology and relates to a method for synthesizing optically pure α-amino acid compounds. More specifically, this invention provides a two-step method for synthesizing a series of optically pure α-amino acid compounds using chiral imines and α-halogenated geminitrogen compounds as starting materials. Background Technology
[0002] Alpha-amino acids are the basic building blocks of proteins and have significant biological importance. They also participate in metabolic pathways, such as serving as neurotransmitter precursors (e.g., glutamate, γ-aminobutyric acid) or as an energy source. Furthermore, amino acids can also act as chiral pools, playing a crucial role in ligand design and total synthesis.
[0003] As the requirements for the variety and quality of amino acids increase, researchers have developed various methods to synthesize different types of natural and non-natural amino acids. For example, enzyme-promoted methods utilize the high stereoselectivity of enzymes to synthesize chiral α-amino acids through asymmetric synthesis or deracemification reactions. While these methods offer mild reaction conditions, high stereoselectivity, and are environmentally friendly, making them suitable for industrial production, poor substrate compatibility and the poor stability of some enzymes limit their application. Asymmetric Strecker reactions are also a common method for preparing chiral α-amino acids. Although this method can yield the corresponding amino acid product through simple cyano hydrolysis, it often requires high temperatures and long reaction times, and the synthesis steps of the ligands or chiral small molecule catalysts used in the reaction are cumbersome. These drawbacks limit the application of this method to some extent. Furthermore, α-imine esters are often used to synthesize α-amino acids. For example, the asymmetric addition reaction of Grignard reagents with α-imine esters can directly yield protected chiral amino acids; however, due to the double-coordinate chelation of the ester imine, severe background reactions often occur, resulting in low enantioselectivity.
[0004] Despite significant progress in the synthesis of chiral α-amino acids, developing more efficient and practical synthetic methods remains an important research direction. Currently, chiral catalysts and chiral amines are common strategies for controlling the chiral sites of amino acids. However, the cumbersome synthetic steps of chiral ligands and catalysts limit the efficiency of amino acid synthesis to some extent. Ellman imines have attracted considerable attention in the field of chiral synthesis due to their simple preparation methods, good stability, and ability to achieve high diastereoselectivity in the reaction. Ellman imine esters can undergo addition reactions with metal reagents to yield the corresponding chiral amino acid derivatives, but these reactions typically cannot achieve excellent diastereoselectivity control. Given the crucial role of amino acids in drug development, biochemistry, and materials science, developing a non-metallic, mild, green, and simple optically pure amino acid synthesis method is particularly urgent. This will not only help reduce synthesis costs but also improve the sustainability and environmental friendliness of the reaction, providing stronger support for the widespread application of chiral amino acids. Summary of the Invention
[0005] To address the shortcomings of existing technologies, the present invention aims to provide a method for synthesizing optically pure α-amino acid compounds. This method offers advantages such as readily available and inexpensive raw materials, environmental friendliness, and a diastereomeric ratio (dr value) greater than 50:1. It not only provides new ideas for the synthesis of natural amino acids but also offers a novel method for the synthesis of non-natural amino acids.
[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0007] Step 1: In a first organic solvent, using the α-halogenated geminiboron compound shown in formula (1) and the chiral imine shown in formula (2) as raw materials, the reaction is stirred under the action of a first base at a first temperature and a second temperature to obtain the geminiboron-substituted aziridine compound shown in formula (3).
[0008] Step 2: Using the compound shown in formula (3) as a raw material, the mixture is stirred and reacted in a second organic solvent under the action of a second base and an oxidant to obtain the α-amino acid compound shown in formula (4).
[0009] The reaction process is shown in equation A below:
[0010]
[0011] In formula A,
[0012] X represents chlorine, bromine, or iodine; R 1 It is alkyl, aryl, or hydrogen; R 2The following are alkyl, alkoxy, aryl, substituted aryl (including aryl groups with mono- or polysubstituted halogens, pseudohalogens, alkyl groups, alkoxy groups, aryl groups, etc., at the ortho, meta, or para positions of the benzene ring), heteroaryl (including 2-furanyl, 2-thienyl, 3-indolyl, etc.), substituted heteroaryl (including heteroaryl groups with mono- or polysubstituted halogens, pseudohalogens, alkyl groups, alkoxy groups, aryl groups, etc., at the ortho, meta, or para positions of the heterocycle), alkenyl, substituted alkenyl (including monosubstituted alkenyl, disubstituted alkenyl, trisubstituted alkenyl), alkynyl, substituted alkynyl (including alkyl-substituted alkynyl, aryl-substituted alkynyl, silyl-substituted alkynyl); R 3 Substituents include hydrogen, alkyl, aryl, etc.; R 4 Substituents include alkyl, aryl, etc.
[0013] Preferably, X is chlorine; R 1 It is an alkyl group; R 2 It is aryl; R 3 It is hydrogen; R 4 It is an alkyl group.
[0014] Among them, the compounds shown in formulas (2), (3), and (4) can be the above structures or their enantiomers.
[0015] Among them, B(OR) 1 )2 represents boric acid (B(OH)2), pinacol borate (Bpin), borate catechol ester (Bcat), borate neopentyl glycol ester (Bneo), borate (2-methyl-2,4-pentanediol) ester, borate 2,4-dimethyl-2,4-pentanediol ester, borate (-)-pinenediol ester, and borate (+)-pinenediol ester.
[0016] In step 1, the first organic solvent is selected from any one or a mixture of multiple types of solvents such as alkane solvents, aromatic solvents, alcohol solvents, nitrile solvents, ether solvents, ketone solvents, amide solvents, chloroalkane solvents, and sulfoxide solvents; preferably, it is THF (tetrahydrofuran).
[0017] In step 1, the first base is selected from any one or a mixture of multiple organic bases such as lithium diisopropylaminol LDA, lithium tetramethylpiperidine LTMP, lithium bistrimethylsilylaminol LHMDS, lithium bistrimethylsilylaminol NaHMDS, potassium bistrimethylsilylaminol KHMDS, n-butyllithium n-BuLi, and methyllithium MeLi; preferably, it is lithium diisopropylaminol LDA.
[0018] In step 1, the molar ratio of the α-halogenated gemini compound shown in formula (1), the chiral imine shown in formula (2), and the first base is (1-3):(1-3):(1-3); preferably, it is 1.5:1.0:1.3.
[0019] In step 1, the first temperature of the reaction is -100℃ to 0℃; preferably, it is -78℃.
[0020] In step 1, the reaction time at the first temperature is 0.5 to 12 hours; preferably, it is 2 hours.
[0021] In step 1, the second temperature of the reaction is 0°C to 60°C; preferably, it is 25°C.
[0022] In step 1, the reaction time at the second temperature is 0.5 to 12 hours; preferably, it is 0.5 hours.
[0023] In step 2, the second organic solvent is selected from any one or a mixture of multiple types of solvents such as alkane solvents, aromatic solvents, alcohol solvents, nitrile solvents, ether solvents, ketone solvents, amide solvents, chloroalkane solvents, and sulfoxide solvents; preferably, it is tetrahydrofuran.
[0024] In step 2, the second alkali is selected from any one or a mixture of multiple inorganic alkalis such as lithium acetate, sodium acetate, potassium acetate, cesium acetate, lithium trifluoroacetate, sodium trifluoroacetate, potassium trifluoroacetate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, lithium hydroxide monohydrate, cesium hydroxide monohydrate, potassium phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate; preferably, it is sodium hydroxide.
[0025] In step 2, the oxidant is selected from any one or a mixture of multiple of hydrogen peroxide, sodium perborate, urea peroxide, etc.; preferably, it is hydrogen peroxide.
[0026] In step 2, the molar ratio of the gemiboron-substituted aziridine compound, the oxidant, and the second base shown in formula (3) is (1-3):(1-10):(1-10); preferably, it is 1:3:3.
[0027] In step 2, the reaction temperature is -100℃ to 60℃; preferably, it is 0℃.
[0028] In step 2, the reaction time is 0.5 to 12 hours; preferably, it is 0.5 hours.
[0029] In step 2, the post-treatment method of the reaction solution is as follows: After the reaction is completed, saturated sodium sulfite is added to quench the reaction, water is added to dilute, the aqueous phase is washed three times with methyl tert-butyl ether, and the organic phase is discarded. The pH of the obtained aqueous phase is adjusted to 2-3 with 1.0M hydrochloric acid solution and stirred at room temperature for 10 minutes. After stirring, the pH is adjusted to 11-12 with 1.0M sodium hydroxide aqueous solution, the aqueous phase is washed three times with methyl tert-butyl ether, and the organic phase is discarded. The pH of the obtained aqueous phase is then adjusted to 2-3 with 1.0M hydrochloric acid solution, the aqueous phase is extracted three times with methyl tert-butyl ether, the organic phases are combined and dried with anhydrous sodium sulfate. The chiral α-amino acid compound shown in formula (4) is obtained after removing the solvent by vacuum distillation.
[0030] In one specific implementation, the method includes the following steps:
[0031] Step 1: Using α-chlorogabionate methane as shown in formula (1) and chiral imine as shown in formula (2) as raw materials, the reaction was carried out at -78°C for 2 hours under the action of lithium diisopropylaminol LDA, and then stirred at room temperature for 0.5 hours. After the reaction was completed, the reaction solution was post-treated to obtain the compound shown in formula (3).
[0032] Step 2: Using the compound shown in formula (3) as a raw material, sodium hydroxide as a base and hydrogen peroxide as an oxidant, the mixture is stirred and reacted in an organic solvent. After post-treatment of the reaction solution, the α-amino acid compound shown in formula (4) is obtained.
[0033] The reaction process is shown in equation A' below:
[0034]
[0035] The present invention also provides chiral aryl / alkyl / alkenyl substituted α-amino acid compounds prepared by the above method.
[0036] The present invention also provides an α-amino acid compound (a chiral aryl / alkyl / alkenyl substituted α-amino acid compound), the structure of which is shown below:
[0037]
[0038] Among them, R 2 R 3 R 4 The definition is the same as shown in equation A.
[0039] Preferably, R 2 It is aryl; R 3 It is hydrogen; R 4 It is an alkyl group.
[0040] Specifically, the chiral α-amino acid compound is as follows:
[0041]
[0042] The present invention also provides a method for removing nitrogen protecting groups and replacing other nitrogen protecting groups from the chiral aryl / alkyl substituted α-amino acid compounds, the reaction process of which is shown in Formula B below.
[0043]
[0044] The present invention also provides an intermediate, the structure of which is shown below:
[0045]
[0046] Among them, R 1 R 2 R 3 R 4 The definition is the same as that described in formula A.
[0047] The present invention also provides the application of the methods described above, or the α-amino acid compounds described above, in large-scale industrial production, efficient preparation of chiral α-amino acid compounds, highly stereoselective preparation of chiral α-amino acid compounds, synthesis of α-natural and non-natural amino acid compounds, reduction of synthesis costs, improvement of reaction sustainability and environmental friendliness, and drug synthesis.
[0048] The beneficial effects of this invention include: compared with the prior art, this invention features simple operation, readily available raw materials and reagents, mild conditions, a green and environmentally friendly reaction system, and easy product separation and purification. It is suitable for synthesizing various highly functionalized chiral α-amino acid compounds. It is particularly suitable for large-scale industrial production, enabling the efficient, high-yield, and highly stereoselective preparation of high-purity chiral α-amino acid compounds, thus broadening the synthetic methods for non-natural α-amino acid compounds. The yield can reach up to 95%, with a high diastereomeric ratio (dr > 50:1). Attached Figure Description
[0049] Figure 1 For compound 4a 1 H-NMR nuclear magnetic resonance spectrum;
[0050] Figure 2 For compound 4b 1 H-NMR nuclear magnetic resonance spectrum;
[0051] Figure 3 For compound 4c 1 H-NMR nuclear magnetic resonance spectrum;
[0052] Figure 4 For compound 4d 1 H-NMR nuclear magnetic resonance spectrum;
[0053] Figure 5 For compound 4e 1 H-NMR nuclear magnetic resonance spectrum;
[0054] Figure 6 For compound 4f 1 H-NMR nuclear magnetic resonance spectrum;
[0055] Figure 7 4g of compound 1 H-NMR nuclear magnetic resonance spectrum;
[0056] Figure 8 For compound 4h 1 H-NMR nuclear magnetic resonance spectrum;
[0057] Figure 9 For compound 4i 1 H-NMR nuclear magnetic resonance spectrum;
[0058] Figure 10 For compound 4j 1 H-NMR nuclear magnetic resonance spectrum;
[0059] Figure 11 For compound 4k 1 H-NMR nuclear magnetic resonance spectrum;
[0060] Figure 12 For compound 4l 1 H-NMR nuclear magnetic resonance spectrum;
[0061] Figure 13 For compound 4m 1 H-NMR nuclear magnetic resonance spectrum;
[0062] Figure 14 For compound 4n 1 H-NMR nuclear magnetic resonance spectrum;
[0063] Figure 15 For compound 4o 1 H-NMR nuclear magnetic resonance spectrum;
[0064] Figure 16 For compound 4p 1 H-NMR nuclear magnetic resonance spectrum;
[0065] Figure 17 For compound 4q 1 H-NMR nuclear magnetic resonance spectrum;
[0066] Figure 18 For compound 4r 1 H-NMR nuclear magnetic resonance spectrum;
[0067] Figure 19 For compound 4s 1 H-NMR nuclear magnetic resonance spectrum;
[0068] Figure 20 For compound 4t 1 H-NMR nuclear magnetic resonance spectrum;
[0069] Figure 21 For compound 4u 1 H-NMR nuclear magnetic resonance spectrum;
[0070] Figure 22 For compound 4v 1 H-NMR nuclear magnetic resonance spectrum;
[0071] Figure 23 For compound 4w 1 H-NMR nuclear magnetic resonance spectrum;
[0072] Figure 24 For compound 4x 1 H-NMR nuclear magnetic resonance spectrum;
[0073] Figure 25 For compound 4y 1 H-NMR nuclear magnetic resonance spectrum;
[0074] Figure 26 For compound 4z 1 H-NMR nuclear magnetic resonance spectrum;
[0075] Figure 27 For compound 4aa 1 H-NMR nuclear magnetic resonance spectrum;
[0076] Figure 28 For compound 4ab 1 H-NMR nuclear magnetic resonance spectrum;
[0077] Figure 29 For compound 4ac 1 H-NMR nuclear magnetic resonance spectrum;
[0078] Figure 30 For compound 4ad 1 Nuclear magnetic resonance spectrum of H-NMR. Detailed Implementation
[0079] The present invention will now be described in further detail with reference to the accompanying drawings and specific embodiments.
[0080] Example 1: Preparation of optically pure α-amino acid 4a
[0081] Step 1: α-Chloroglucinolate pinacol ester methane compound 1a (90.2 mg, 0.30 mmol) was added to a 15 mL flask equipped with a magnetic stirrer, and the air in the flask was purged with argon. Then, 2 mL of ultra-dry tetrahydrofuran was added, followed by cooling to –78 °C. Diisopropylaminolithium (LDA) (2.0 M in THF / n-heptane / ethylbenzene, 0.13 mL, 0.26 mmol) was added dropwise, and the mixture was stirred for 10 minutes. Then, (S,E)-N-(4-methoxybenzyl)-2-methylpropane-2-sulfinamide 2a (47.9 mg, 0.20 mmol) dissolved in 1 mL of ultra-dry tetrahydrofuran was slowly added to the system, and the mixture was stirred at –78 °C for 2 hours. The mixture was then stirred at room temperature for 30 minutes. After the reaction was complete, the mixture was diluted with 2 mL of methyl tert-butyl ether and filtered through silica gel, followed by rinsing with methyl tert-butyl ether. The resulting filtrate was distilled under reduced pressure to obtain crude product 3a, which was used directly in the next step.
[0082] Step 2: Add crude product 3a (0.20 mmol) to a 20 mL flask equipped with a magnetic stirrer, add 1 mL of tetrahydrofuran, and then cool to 0 °C. Add hydrogen peroxide (1.0 M in water, 0.60 mL, 0.60 mmol) and sodium hydroxide (1.0 M in water, 0.60 mL, 0.60 mmol) sequentially, and stir at 0 °C for 30 minutes. After the reaction is complete, quench the reaction with saturated sodium sulfite, dilute with water, wash the aqueous phase three times with methyl tert-butyl ether, and discard the organic phase. Adjust the pH of the resulting aqueous phase to 2–3 with 1.0 M hydrochloric acid solution and stir at room temperature for 10 minutes. After stirring, adjust the pH to 11–12 with 1.0 M sodium hydroxide aqueous solution, wash the aqueous phase three times with methyl tert-butyl ether, and discard the organic phase. Adjust the pH of the resulting aqueous phase again to 2–3 with 1.0 M hydrochloric acid solution, extract the aqueous phase three times with methyl tert-butyl ether, combine the organic phases, and dry with anhydrous sodium sulfate. The solvent was removed by vacuum distillation to obtain compound 4a. The structure of the product was confirmed by 1H NMR spectroscopy and high-resolution mass spectrometry. Yield 88%, >50:1dr.
[0083]
[0084] Spectral analysis data 3a:
[0085] 1 H NMR (600MHz, CDCl3): δ7.34 (d, J = 8.4Hz, 2H), 6.81 (d, J = 8.4Hz, 2H), 3.77 (s, 3H) ,3.30(s,1H),1.36(s,9H),1.26(s,6H),1.24(s,6H),1.08(s,6H),1.00(s,6H); 13C NMR (150MHz, CDCl3): δ158.9,130.6,128.1,113.4,83.5,82.2,57.5,55.3,42.7,25.0,24.7,24.5,22.8; 11 B NMR (193MHz, CDCl3): δ30.0, 27.3; HRMS (ESI-TOF): m / z calculated for C 25 H 41 B2NNaO6S + [M+Na] + 528.2742, found 528.2736.
[0086] Spectral analysis data 4a:
[0087] 1 H NMR (500MHz, CDCl3): δ7.33(d,J=8.4Hz,2H),6.88(d,J=8.6Hz,2H),5.04-5.00(m,2H),3.80(s,3H),1.25(s,9H)( Figure 1 ); 13 C NMR (125MHz, CDCl3): δ172.7,159.7,129.2,128.7,114.1,60.6,56.5,55.3,22.7; HRMS (ESI-TOF): m / zcalculated forC 13 H 19 NNaO4S + [M+Na] + 308.0927, found 308.0924.
[0088] Example 2:
[0089] (S,E)-N-(4-iodobenzyl)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4b (shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 88% and >50:1dr.
[0090]
[0091] Spectral analysis data 4b:
[0092] 1H NMR (500MHz, (CD3)2SO): δ7.72(d,J=7.9Hz,2H),7.22(d,J=8.0Hz,2H),5.61(d,J=5.9Hz,1H),4.89(d,J=5.8Hz,1H),1.11(s,9H)( Figure 2 ); 13 C NMR (125MHz, (CD3)2SO): δ172.0,138.3,137.1,130.0,94.1,60.0,55.4,22.4; HRMS (ESI-TOF): m / z calculated forC 12 H 16 INNaO3S + [M+Na] + 403.9788, found 403.9789.
[0093] Example 3:
[0094] (S,E)-N-(4-bromobenzyl)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4c (shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 87% and >50:1dr.
[0095]
[0096] Spectral analysis data 4c:
[0097] 1 H NMR (600MHz, CDCl3): δ7.49(d,J=8.3Hz,2H),7.29(d,J=8.2Hz,2H),5.07-5.03(m,2H),1.25(s,9H)( Figure 3 ); 13 C NMR (150MHz, CDCl3): δ172.0,136.2,131.9,129.2,122.6,60.6,56.8,22.6; HRMS (ESI-TOF): m / z calculated for C 12 H 16 BrNNaO3S + [M+Na] + 355.9926, found 355.9929.
[0098] Example 4:
[0099] (S,E)-N-(3-bromobenzyl)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4d (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 84% and >50:1dr.
[0100]
[0101] Spectral analysis data 4d:
[0102] 1 H NMR (600MHz, CDCl3): δ7.57(s,1H),7.45(d,J=8.0Hz,1H),7.36(d,J=7.8Hz,1H ),7.24-7.22(m,1H),5.14(d,J=5.0Hz,1H),5.06(d,J=4.6Hz,1H),1.26(s,9H)( Figure 4 ); 13 C NMR (150MHz, CDCl3): δ171.9,139.4,131.5,130.5,130.2,126.2,122.7,60.7,56.9,22.6; HRMS (ESI-TOF): m / z calculated for C 12 H 16 BrNNaO3S + [M+Na] + 355.9926, found 355.9923.
[0103] Example 5:
[0104] (S,E)-N-(2-bromobenzyl)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4e (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 87% and >50:1dr.
[0105]
[0106] Spectral analysis data 4e:
[0107] 1 H NMR (600MHz, CD3OD): δ7.63-7.62(m,1H),7.43-7.42(m,1H),7.38-7.35(m,1H),7.25-7.22(m,1H),5.47(s,1H),1.19(s,9H)( Figure 5 ); 13C NMR (150MHz, CD3OD): δ173.2,138.7,134.3,131.1,129.0,125.3,61.6,57.3,22.8; HRMS (ESI-TOF): m / z calculated forC 12 H 16 BrNNaO3S + [M+Na] + 355.9926, found 355.9922.
[0108] Example 6:
[0109] (S,E)-2-methyl-N-(2-methylbenzyl)propane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4f (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 95% and >50:1dr.
[0110]
[0111] Spectral analysis data 4f:
[0112] 1 H NMR (600MHz, CDCl3): δ7.33-7.31(m,1H),7.22-7.17(m,3H),5.29(d,J=4.3Hz,1H),5.16(d,J=4.6Hz,1H),2.45(s,3H),1.21(s,9H)( Figure 6 ); 13 C NMR (125MHz, CDCl3): δ172.9,136.7,135.6,130.8,128.3,127.9,126.2,58.2,56.5,22.6,19.5; HRMS (ESI-TOF): m / z calculated for C 13 H 19 NNaO3S + [M+Na] + 292.0978, found 292.0973.
[0113] Example 7:
[0114] (S,E)-N-(4-cyanobenzylidene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. After steps 1 and 2, 4g of the target product (as shown in the structural formula below) was obtained with a yield of 81% and >50:1dr.
[0115]
[0116] Spectral analysis data 4g:
[0117] 1 H NMR (600MHz, CDCl3): δ7.67(d,J=8.2Hz,2H),7.55(d,J=8.3Hz,2H),5.14(s,2H),1.26(s,9H)( Figure 7 ); 13 CNMR (150MHz, CDCl3): δ171.4,142.2,132.5,128.3,118.3,112.4,60.8,57.0,22.6; HRMS (ESI-TOF): m / z calculated for C 13 H 16 N2NaO3S + [M+Na] + 303.0774, found 303.0767.
[0118] Example 8:
[0119] (S,E)-2-methyl-N-(4-(trifluoromethyl)benzyl)propane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4h (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 85% and >50:1dr.
[0120]
[0121] Spectral analysis data 4h:
[0122] 1 H NMR (600MHz, CDCl3): δ7.63(d,J=8.2Hz,2H),7.55(d,J=8.1Hz,2H),5.19-5.16(m,2H),1.25(s,9H)( Figure 8 ); 13 C NMR (150MHz, CDCl3): δ171.8, 141.1, 130.7 (q, J = 32.5Hz), 127.9, 125.7 (q, J = 3.7Hz), 123.9 (q, J = 272.3Hz), 60.9, 56.9, 22.9; 19 F NMR(471MHz, CDCl3)δ–62.7; HRMS(ESI-TOF):m / z calculated for C 13 H 16 F3NNaO3S+ [M+Na] + 346.0695, found 346.0690.
[0123] Example 9:
[0124] Using tert-butyl(S,E)-4-(((tert-butylsulfinyl)imino)methyl)benzoate instead of 2a in Example 1 of the present invention, and with other conditions the same as in Example 1 of the present invention, the target product 4i (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 83% and >50:1dr.
[0125]
[0126] Spectral analysis data 4i:
[0127] 1 H NMR (600MHz, CDCl3): δ7.98(d,J=8.3Hz,2H),7.47(d,J=8.4Hz,2H),5.16-5.14(m,2H),1.59(s,9H),1.24(s,9H)( Figure 9 ); 13 C NMR (125MHz, CDCl3): δ171.9,165.3,141.5,132.1,129.8,127.4,81.2,61.1,56.8,28.2,22.6; HRMS (ESI-TOF): m / z calculated for C 17 H 25 NNaO5S + [M+Na] + 378.1346, found 378.1343.
[0128] Example 10:
[0129] (S,E)-2-methyl-N-((2-methylpyrimidin-5-yl)methylene)propane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4j (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 55% and >50:1dr.
[0130]
[0131] Spectral analysis data 4j:
[0132] 1H NMR (500MHz, CDCl3): δ8.76(s,2H),5.15(d,J=3.3Hz,1H),5.00(d,J=3.7Hz,1H),2.74(s,3H),1.27(s,9H)( Figure 10 ); 13 C NMR (125MHz, CDCl3): δ171.2,167.3,156.3,128.8,56.7,56.3,25.0,22.6; HRMS (ESI-TOF): m / z calculated for C 11 H 18 N3O3S + [M+H] + 272.1063, found 272.1072.
[0133] Example 11:
[0134] The target product 4k (as shown in the following structural formula) was obtained by replacing 2a in Example 1 of the present invention with tert-butyl(S,E)-3-(((tert-butylsulfinyl)imino)methyl)-1H-indole-1-carboxylic acid ester, with other conditions the same as in Example 1 of the present invention, and the yield was 76%, >50:1dr.
[0135]
[0136] Spectral analysis data 4k:
[0137] 1 H NMR (600MHz, CDCl3): δ8.16(s,1H),7.69(s,1H),7.63(d,J=7.9Hz,1H),7.33- 7.30(m,1H),7.22-7.20(m,1H),5.32-5.26(m,2H),1.66(s,9H),1.17(s,9H)( Figure 11 ); 13 C NMR (150MHz, CDCl3): δ172.3,149.4,135.9,128.0,125.4,124.7,122.7,120.0,116.4,115.3,84.0,56.6,54.6,28.1,22.7; HRMS (ESI-TOF): m / z calculated for C 19 H 26 N2NaO5S + [M+Na] + 417.1455, found 417.1449.
[0138] Example 12:
[0139] (S,E)-2-methyl-N-(thiophene-2-ylmethylene)propane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4l (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 75% and >50:1dr.
[0140]
[0141] Spectral analysis data 4l:
[0142] 1 H NMR (600MHz, CD3CD): δ7.39(d,J=5.1Hz,1H),7.15(d,J=3.5Hz,1H),7.00(dd,J=5.1,3.5Hz,1H),5.30(s,1H),1.26(s,9H)( Figure 12 ); 13 C NMR (150MHz, CD3CD): δ173.2,141.6,127.91,127.89,127.2,58.2,57.5,23.0; HRMS (ESI-TOF): m / z calculated forC 10 H 15 NNaO3S2 + [M+Na] + 284.0386, found 284.0382.
[0143] Example 13:
[0144] (S,E)-N-(3,5-di-tert-butylbenzyl)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4m (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 81% and >50:1dr.
[0145]
[0146] Spectral analysis data 4m:
[0147] 1 H NMR (500MHz, CDCl3): δ7.36(s,1H),7.26(s,2H),5.16(d,J=4.3Hz,1H),5.11(d,J=4.1Hz,1H),1.31(s,18H),1.27(s,9H)( Figure 13 ); 13C NMR (125MHz, CDCl3): δ172.8,150.9,136.2,122.3,121.7,61.4,56.6,34.9,31.4,22.7; HRMS (ESI-TOF): m / z calculated for C 20 H 33 NNaO3S + [M+Na] + 390.2073, found 390.2079.
[0148] Example 14:
[0149] (S,E)-N-(2-(benzo[d][1,3]dioxolane-5-yl)ethylene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4n (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 84% and >50:1dr.
[0150]
[0151] Spectral analysis data 4n:
[0152] 1 H NMR (600MHz, CDCl3): δ6.71(d,J=7.9Hz,1H),6.67(s,1H),6.62(d,J=8.0Hz,1H),5.92-5.91(m,2H),4.43(d ,J=8.4Hz,1H),4.10-4.07(m,1H),3.07(dd,J=14.0,5.1Hz,1H),2.81(dd,J=14.0,8.5Hz,1H),1.16(s,9H)( Figure 14 ); 13 CNMR(150MHz, CDCl3): δ173.5,147.6,146.4,130.1,122.8,109.9,108.1,100.9,60.6,56.8,39.9,22.6; HRMS(ESI-TOF):m / z calculated for C 14 H 18 NO5S - [MH] - 312.0911, found 312.0919.
[0153] Example 15:
[0154] (S,E)-N-((1-(2,2-difluorobenzo[d][1,3]dioxolane-5-yl)cyclopropyl)methylene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4o (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 84% and >50:1dr.
[0155]
[0156] Spectral analysis data 4o:
[0157] 1 H NMR (600MHz, CDCl3): δ7.02-7.03(m,2H),6.91(d,J=8.8Hz,1H),4.39(d,J=6.9Hz,1H),3.56(d,J=6 .9Hz,1H),1.28(s,9H),1.26-1.23(m,1H),0.98-0.94(m,1H),0.92-0.89(m,1H),0.86-0.83(m,1H)( Figure 15 ); 13 C NMR (150MHz, CDCl3): δ171.9, 143.3, 142.8, 136.6, 131.6 (t, J = 254.9Hz), 126.1, 112.1, 108.8, 65.6, 57.0, 29.4, 22.8, 11.8, 11.7; 19 F NMR (471MHz, CDCl3): –49.8, –49.9; HRMS (ESI-TOF): m / z calculated for C 16 H 19 F2NNaO5S + [M+Na] + 398.0844, found 398.0846.
[0158] Example 16:
[0159] (S,E)-N-(3-(benzo[d][1,3]dioxolane-5-yl)propene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4p (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 68% and >50:1dr.
[0160]
[0161] Spectral analysis data 4p:
[0162] 1 H NMR (600MHz, CDCl3): δ6.71(d,J=7.9Hz,1H),6.65(d,J=1.7Hz,1H),6.60(dd,J=7.9,1.7Hz,1H),5.91(s,2H),4 .53(d,J=8.1Hz,1H),3.90-3.86(m,1H),2.67-2.56(m,2H),2.09-2.03(m,1H),1.94-1.88(m,1H),1.30(s,9H)( Figure 16 ); 13 C NMR (150MHz, CDCl3): δ174.1,147.6,145.8,134.5,121.2,108.8,108.2,100.8,58.3,56.8,36.2,31.2,22.8; HRMS (ESI-TOF): m / z calculated for C 15 H 21 NNaO5S + [M+Na] + 350.1033, found 350.1023.
[0163] Example 17:
[0164] (S,E)-N-(3-(2,4-difluorophenyl)propylidene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4q (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 89% and >50:1dr.
[0165]
[0166] Spectral analysis data 4q:
[0167] 1 H NMR (600MHz, CDCl3): δ7.15-7.11(m,1H),6.81-6.74(m,2H),4.57(d,J=7.9Hz,1H),3. 91-3.88(m,1H),2.71-2.67(m,2H),2.11-2.05(m,1H),1.95-1.89(m,1H),1.31(s,9H)( Figure 17 ); 13C NMR (150MHz, CDCl3): δ173.8,161.6(dd,J=246.8,11.8Hz), 160.9(dd,J=247.9,11.7Hz), 131.1(dd,J=9.5,6.4 Hz), 123.4 (dd, J=16.1, 3.8Hz), 111.1 (dd, J=20.8, 3.8Hz), 103.6 (t, J=25.7Hz), 58.4, 56.8, 34.5, 24.4, 22.7; 19 F NMR (471MHz, CDCl3): –113.01 (d, J=5.8Hz), –114.27 (d, J=7.1Hz); HRMS (ESI-TOF): m / z calculated for C 14 H 19 F2NNaO3S + [M+Na] + 342.0946, found 342.0947.
[0168] Example 18:
[0169] Replacing 2a in Example 1 of this invention with (S,E)-N-(6,6-diisopropyl-7-methyloct-4-yn-1-ylidene)-2-methylpropane-2-sulfinamide, and with other conditions the same as in Example 1, the target product 4r (as shown in the structural formula below) was obtained through steps 1 and 2, with a yield of 70% and a ratio >50:1dr.
[0170]
[0171] Spectral analysis data 4r:
[0172] 1 H NMR (600MHz, CDCl3): δ4.46 (d, J = 8.7Hz, 1H), 4.06-4.03 (m, 1H), 2.39-2.36 (m ,2H),2.08-2.02(m,1H),1.84-1.78(m,1H),1.29(s,9H),1.09-1.01(m,21H)( Figure 18 ); 13 C NMR (150MHz, CDCl3): δ174.0,106.5,81.9,57.9,56.8,33.2,22.7,18.6,16.3,11.2; HRMS (ESI-TOF): m / z calculated for C 18 H 37 NNaO3SSi + [M+Na]+ 410.2156, found 410.2156.
[0173] Example 19:
[0174] (S,E)-N-(cyclopropylmethylene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4s (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 72% and >50:1dr.
[0175]
[0176] Spectral analysis data 4s:
[0177] 1 H NMR (600MHz, CDCl3): δ4.66 (d, J=7.6Hz, 1H), 4.09 (dd, J=7.7, 3.3Hz, 1H), 1.31 (s, 9H), 0.81-0.74 ( m,2H),0.62-0.56(m,2H),0.48-0.38(m,3H),0.28-0.24(dq,J=9.8,5.0Hz,1H),0.21-0.16(m,3H)( Figure 19 ); 13 C NMR (150MHz, CDCl3): δ173.8, 62.9, 56.6, 51.7, 22.9, 13.4, 11.1, 5.4, 2.8, 2.6, 2.5; HRMS (ESI-TOF): m / z calculated for C 13 H 23 NNaO3S + [M+Na] + 296.1291, found 296.1283.
[0178] Example 20:
[0179] The target product 4t (as shown in the following structural formula) was obtained by replacing 2a in Example 1 of the present invention with (S,E)-3-(((tert-butylsulfinyl)imino)methyl)azacyclobutane-1-carboxylic acid ester, and other conditions were the same as in Example 1 of the present invention. The yield was 73%, >50:1dr.
[0180]
[0181] Spectral analysis data 4t:
[0182] 1H NMR (500MHz, CDCl3): δ4.61 (d, J = 8.0Hz, 1H), 4.02-3.97 (m, 2H), 3.94-3.91 (m, 1H), 3.85-3.82(m,1H),3.77-3.74(m,1H),2.89-2.87(m,1H),1.42(s,9H),1.29(s,9H)( Figure 20 ); 13 C NMR (125MHz, CDCl3): δ172.3,156.1,79.7,60.2,57.2,50.6,32.0,28.3,22.7; HRMS (ESI-TOF): m / z calculated for C 14 H 26 N2NaO5S + [M+Na] + 357.1455, found 357.1451.
[0183] Example 21:
[0184] The target product 4u (as shown in the following structural formula) was obtained by replacing 2a in Example 1 of the present invention with (S)-2-methyl-N-((E)-(tetrahydrofuran-3-yl)methylene)propane-2-sulfinyl(1:1dr)amine, and other conditions were the same as in Example 1 of the present invention. The yield was 82% and the product was 1:1dr.
[0185]
[0186] Spectral analysis data 4u:
[0187] 1 H NMR (500MHz, CDCl3): δ4.56 (dd, J=17.6, 8.8Hz, 1H), 3.89-3.70 (m, 4H), 3.66-3.62 ( m,1H),2.71-2.56(m,1H),2.06-1.84(m,1H),1.85-1.74(m,1H),1.30-1.29(m,9H)( Figure 21 ); 13 C NMR (150MHz, CDCl3): δ173.4,173.4,70.1,69.7,68.1,68.0,61.5,60.3,57.113,57.107,42.94,42.87,28.9,28.5,22.8,22.8; HRMS (ESI-TOF): m / z calculated forC 10 H 19 NNaO4S+ [M+Na] + 272.0927, found 272.0935.
[0188] Example 22:
[0189] (S,E)-N-((4,4-difluorocyclohexyl)methylene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4v (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 89% and >50:1dr.
[0190]
[0191] Spectral analysis data 4v:
[0192] 1 H NMR (600MHz, CDCl3): δ4.45 (d, J=7.9Hz, 1H), 3.78 (dd, J=7.9, 5.2Hz, 1H), 2.12-2.10 (m, 2H ),1.87-1.83(m,1H),1.75-1.63(m,4H),1.57-1.50(m,1H),1.44-1.37(m,1H),1.31(s,9H)( Figure 22 ); 13 C NMR (150MHz, CDCl3): δ173.1,122.8(dd,J=242.4,239.4Hz),62.4(d,J=2.3Hz) ,57.2,39.5,33.1(t,J=25.3Hz),32.9(t,J=25.4Hz),23.5(d,J=9.9Hz),22.8; 19 F NMR (471MHz, CDCl3): –92.1 (d, J=236.3Hz), –102.8 (d, J=237.1Hz); HRMS (ESI-TOF): m / z calculated for C 12 H 21 F2NNaO3S + [M+Na] + 320.1102, found 320.1099.
[0193] Example 23:
[0194] The target product 4w (as shown in the following structural formula) was obtained by replacing 2a in Example 1 of the present invention with (S,E)-4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylic acid ester, and other conditions were the same as in Example 1 of the present invention. The yield was 94%, >50:1dr.
[0195]
[0196] Spectral analysis data 4w:
[0197] 1 H NMR (600MHz, CDCl3): δ4.40 (d, J = 8.1Hz, 1H), 4.13 (br, 2H), 3.76-3.73 (m, 1H), 2.66 (br, 2H),1.92-1.87(m,1H),1.64-1.60(m,2H),1.44(s,9H),1.30(s,9H),1.30-1.21(m,2H)( Figure 23 ); 13 C NMR (125MHz, CDCl3): δ173.1,154.8,79.6,62.9,57.1,40.1,28.4,269,22.9; HRMS (ESI-TOF): m / z calculated for C 16 H 30 N2NaO5S + [M+Na] + 385.1768, found 385.1765.
[0198] Example 24:
[0199] (S)-N-((E)-cyclohex-3-en-1-ylmethylene)-2-methylpropane-2-sulfinamide (1:1dr) was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4x (as shown in the following structural formula) was obtained through steps 1 and 2, with a yield of 92% and a ratio of 1:1dr.
[0200]
[0201] Spectral analysis data 4x:
[0202] 1 H NMR (600MHz, CDCl3): δ5.67-5.61(m,2H),4.46-4.43m,1H),3.82-3.76(m,1H),2.09-1.72(m,6H),1.46-1.39(m,1H),1.30(s,9H)( Figure 24 );13 C NMR (150MHz, CDCl3): δ173.64,173.58,126.9,126.8,125.6,125.4,63.1,62.9,57.01,5 6.97,37.7,37.6,28.0,26.5,25.7,25.0,24.8,23.6,22.90,22.88; HRMS(ESI-TOF):m / z calculated forC 12 H 21 NNaO3S + [M+Na] + 282.1134, found 282.1128.
[0203] Example 25:
[0204] (S)-N-((E)-((3S,5S,7S)-adamantane-2-yl)methylene)-2-methylpropane-2-sulfinamide was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4y (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 86% and >50:1dr.
[0205]
[0206] Spectral analysis data 4y:
[0207] 1 H NMR (600MHz, CDCl3): δ4.25 (d, J = 10.0Hz, 1H), 4.07-4.03 (m, 1H), 2.06-2.00 (m, 2H), 1.90-1.68 (m, 12H), 1.57-1.51 (m, 2H), 1.27 (s, 9H) ( Figure 25 ); 13 C NMR (150MHz, CDCl3): δ174.5,61.0,57.1,47.8,38.6,38.5,38.0,31.7,31.15,29.3,27.8,27.6,27.5,22.9; HRMS (ESI-TOF): m / z calculated for C 16 H 27 NNaO3S + [M+Na] + 336.1604, found 336.1603.
[0208] Example 26: Preparation of optically pure α-amino acid 4z
[0209] Step 1: α-Chloroglucinolate pinacol ester methane compound 1a (90.2 mg, 0.30 mmol) was added to a 15 mL flask equipped with a magnetic stirrer, and the air in the flask was purged with argon. Then, 2 mL of ultra-dry tetrahydrofuran was added, followed by cooling to –78 °C. Diisopropylaminolithium (LDA) (2.0 M in THF / n-heptane / ethylbenzene, 0.13 mL, 0.26 mmol) was added dropwise, and the mixture was stirred for 10 minutes. Then, (S)-N-((E)-((3S,5S,7S)-adamantane-1-yl)methylene)-2-methylpropane-2-sulfinamide 2z (53.4 mg, 0.20 mmol) dissolved in 1 mL of ultra-dry tetrahydrofuran was slowly added to the system while maintaining the temperature at –78 °C and stirring for 2 hours. The mixture was then brought to room temperature and stirred for 30 minutes. After the reaction was complete, the mixture was diluted with methyl tert-butyl ether and filtered through silica gel, followed by rinsing with methyl tert-butyl ether. The resulting filtrate was distilled under reduced pressure to obtain crude product 3z, which was used directly in the next step.
[0210] Step 2: Add 3z (0.20 mmol) of crude product to a 20 mL flask equipped with a magnetic stirrer, add 1 mL of tetrahydrofuran, and then cool to 0 °C. Add hydrogen peroxide (1.0 M in water, 1.0 mL, 1.0 mmol) and sodium hydroxide (1.0 M in water, 1.0 mL, 1.0 mmol) sequentially, and stir at 0 °C for 30 minutes. After the reaction is complete, quench the reaction with saturated sodium sulfite, dilute with water, wash the aqueous phase three times with methyl tert-butyl ether, and discard the organic phase. Adjust the pH of the resulting aqueous phase to 2–3 with 1.0 M hydrochloric acid solution and stir at room temperature for 10 minutes. After stirring, adjust the pH to 11–12 with 1.0 M sodium hydroxide aqueous solution, wash the aqueous phase three times with methyl tert-butyl ether, and discard the organic phase. Adjust the pH of the resulting aqueous phase again to 2–3 with 1.0 M hydrochloric acid solution, extract the aqueous phase three times with methyl tert-butyl ether, combine the organic phases, and dry with anhydrous sodium sulfate. Compound 4z was obtained by vacuum distillation, and the structure of the product was confirmed by 1H NMR and high-resolution mass spectrometry. Yield 80%, >50:1dr.
[0211]
[0212] Spectral analysis data 4z:
[0213] 1 H NMR (600MHz, CDCl3): δ4.36 (d, J=8.6Hz, 1H), 3.42 (d, J=8.5Hz, 1H), 1.99-1.97 (m,3H),1.70-1.67(m,7H),1.61-1.59(m,3H),1.55-1.52(m,3H),1.33(s,9H)( Figure 26 ); 13 C NMR (125MHz, CDCl3): δ172.5,68.0,57.2,38.5,36.7,36.7,28.3,23.1; HRMS (ESI-TOF): m / z calculated for C 16 H 27 NNaO3S + [M+Na] + 336.1604, found 336.1604.
[0214] Example 27:
[0215] The target product 4aa (as shown in the following structural formula) was obtained by replacing 2a in Example 1 of the present invention with tert-butyl(S,E)-3-(((tert-butylsulfinyl)imino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid ester, and other conditions were the same as in Example 1 of the present invention. The yield was 75%, >50:1dr.
[0216]
[0217] Spectral analysis data 4aa:
[0218] 1 H NMR (600MHz, CDCl3): δ4.47(d,J=7.2Hz,1H),3.96(d,J=7.1Hz,1H),1.96(s,6H),1.42(s,9H),1.30(s,9H)( Figure 27 ); 13 C NMR (125MHz, CDCl3): δ171.5,169.2,80.7,58.6,56.9,50.2,39.5,38.6,27.9,22.8; HRMS (ESI-TOF): m / zcalculated for C 16 H 27 NNaO5S + [M+Na] + 368.1502, found 368.1500.
[0219] Example 28:
[0220] (2S,3S)-2-(((S)-tert-butylsulfinyl)amino)-3-methoxy-3-phenylpropionic acid was used instead of 2a in Example 1 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4ab (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 82% and >50:1dr.
[0221]
[0222] Spectral analysis data 4ab:
[0223] 1 H NMR (600MHz, CDCl3): δ7.33-7.27(m,5H),4.41(d,J=7.6Hz,1H),4.37(d,J=8.9Hz,1H),4.18(dd,J=8.9,7.6Hz,1H),3.22(s,3H),1.03(s,9H)( Figure 28 ); 13 C NMR (150MHz, CDCl3): δ172.6,137.2,128.4,128.3,128.2,84.0,63.8,56.9,22.5; HRMS (ESI-TOF): m / zcalculated for C 14 H 21 NNaO4S + [M+Na] + 322.1083, found 322.1086.
[0224] Example 29: Preparation of optically pure α-amino acid 4ac
[0225] Step 1: α-Chloroglucinolate pinacol ester methane compound 1a (90.2 mg, 0.30 mmol) was added to a 15 mL flask equipped with a magnetic stirrer, and the air in the flask was purged with argon. Then, 2 mL of ultra-dry tetrahydrofuran was added, followed by cooling to –78 °C. Diisopropylaminolithium (LDA) (2.0 M in THF / n-heptane / ethylbenzene, 0.13 mL, 0.26 mmol) was added dropwise, and the mixture was stirred for 10 minutes. Then, (S)-N-((1E,2E)-but-2-ene-1-yl)-2-methylpropane-2-sulfinamide (37.5 mg, 0.20 mmol) dissolved in 1 mL of ultra-dry tetrahydrofuran was slowly added to the system, and the mixture was stirred at –78 °C for 2 hours. The mixture was then stirred at room temperature for 30 minutes. After the reaction was complete, the mixture was diluted with 2 mL of methyl tert-butyl ether and filtered through silica gel, followed by rinsing with methyl tert-butyl ether. The resulting filtrate was distilled under reduced pressure to obtain crude product 3ac, which was used directly in the next step.
[0226] Step 2: Add 3ac (0.20 mmol) of crude product to a 20 mL flask equipped with a magnetic stirrer, along with 2 mL of tetrahydrofuran and 1 mL of deionized water, and then cool to 0 °C. Add hydrogen peroxide (1.0 M in water, 0.60 mL, 0.60 mmol) and sodium bicarbonate (50.6 mg, 0.60 mmol) sequentially, then return to room temperature and stir for 30 minutes. After the reaction is complete, quench the reaction with saturated sodium sulfite, dilute with water, wash the aqueous phase three times with methyl tert-butyl ether, and discard the organic phase. Adjust the pH of the resulting aqueous phase to 2–3 with 1.0 M hydrochloric acid solution and stir at room temperature for 10 minutes. After stirring, adjust the pH to 11–12 with 1.0 M sodium hydroxide aqueous solution, wash the aqueous phase three times with methyl tert-butyl ether, and discard the organic phase. Adjust the pH of the resulting aqueous phase again to 2–3 with 1.0 M hydrochloric acid solution, extract the aqueous phase three times with methyl tert-butyl ether, combine the organic phases, and dry with anhydrous sodium sulfate. The solvent was removed by vacuum distillation to obtain compound 4a. The structure of the product was confirmed by 1H NMR spectroscopy and high-resolution mass spectrometry. Yield 82%, >50:1dr.
[0227]
[0228] Spectral analysis data 4ac:
[0229] 1 H NMR (600MHz, CDCl3): δ5.86-5.80(m,1H),5.48(dd,J=15.1,6.6Hz,1H),4.62(br,1H),4.45-4.43(m,1H),1.72(d,J=6.6Hz,3H),1.28(s,9H)( Figure 29 ); 13 C NMR (150MHz, CDCl3): δ172.9,130.3,126.4,59.7,56.5,22.7,17.7; HRMS (ESI-TOF): m / z calculated for C9H 17 NNaO3S + [M+Na] + 242.0821, found 242.0814.
[0230] Example 30:
[0231] (S,E)-2-methyl-N-(3-methylbut-2-ene-1-yl)propane-2-sulfinamide was used instead of 2z in Example 26 of the present invention, and other conditions were the same as in Example 1 of the present invention. The target product 4ad (as shown in the following structural formula) was obtained by steps 1 and 2, with a yield of 56% and >50:1dr.
[0232]
[0233] Spectral analysis data 4ad:
[0234] 1 H NMR (500MHz, CDCl3): δ5.10(d,J=8.9Hz,1H),4.68-4.64(m,2H),1.78(s,3H),1.76(s,3H),1.26(s,9H)( Figure 30 ); 13 C NMR (125MHz, CDCl3): δ173.6,139.2,120.4,56.3,56.1,25.8,22.6,18.6; HRMS (ESI-TOF): m / z calculated for C 10 H 19 NNaO3S + [M+Na] + 256.0978, found 256.0974.
[0235] As can be seen from the above embodiments and the measured data, the method for preparing optically pure α-amino acid compounds using the method of this application is simple and convenient to operate, the product has high stereoselectivity, the required raw materials are cheap and readily available, it can simplify the synthesis route, improve production efficiency, and the scale-up experiment can be carried out during the synthesis process, making it suitable for industrial production.
[0236] The above are merely preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be considered as limitations on the present invention, and the scope of protection of the present invention should be determined by the scope defined in the claims. For those skilled in the art, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A method for synthesizing optically pure α-amino acid compounds, characterized in that, Includes the following steps: Step 1: In a first organic solvent, using the α-halogenated geminoboron compound shown in formula (1) and the chiral imine compound shown in formula (2) as raw materials, the mixture is stirred and reacted under the action of a first base at a first temperature and a second temperature to obtain the compound shown in formula (3). Step 2: Using the compound shown in formula (3) as a raw material, the mixture is stirred and reacted in a second organic solvent under the action of a second base and an oxidizing agent to obtain the optically pure α-amino acid compound shown in formula (4); the reaction process is shown in formula A below: wherein X is chlorine, bromine, iodine; R 1 is alkyl, aryl, hydrogen; R 2 is alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl; R 3 is hydrogen, alkyl, aryl; R 4 is alkyl, aryl.
2. The method according to claim 1, characterized in that, In step 1, the first organic solvent is any one or a mixture of more than one of alkane solvents, aromatic solvents, alcohol solvents, nitrile solvents, ether solvents, ketone solvents, amide solvents, chloroalkane solvents, and sulfoxide solvents; and / or, the first base is selected from any one or a mixture of more than one of lithium diisopropylamino (LDA), lithium tetramethylpiperidine (LTMP), lithium bis(trimethylsilylamino) (LHMDS), lithium bis(trimethylsilylamino) (NaHMDS), potassium bis(trimethylsilylamino) (KHMDS), lithium n-butyl (n-BuLi), and lithium methyl (MeLi).
3. The method according to claim 1, characterized in that, In step 1, the molar ratio of the α-halogenated geminoboron compound shown in formula (1), the chiral imine shown in formula (2), and the first base is (1-3):(1-3):(1-3).
4. The method according to claim 1, characterized in that, In step 1, the first temperature of the reaction is -100℃ to 0℃; and / or, the reaction time at the first temperature is 0.5 to 12 hours; and / or, the second temperature of the reaction is 0℃ to 60℃; and the reaction time at the second temperature is 0.5 to 12 hours.
5. The method according to claim 1, characterized in that, In step 2, the second alkali is selected from any one or a mixture of more than one of lithium acetate, sodium acetate, potassium acetate, cesium acetate, lithium trifluoroacetate, sodium trifluoroacetate, potassium trifluoroacetate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, lithium hydroxide monohydrate, cesium hydroxide monohydrate, potassium phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate; and / or, the second organic solvent is selected from any one or a mixture of more than one of alkane solvents, aromatic solvents, alcohol solvents, nitrile solvents, ether solvents, ketone solvents, amide solvents, chloroalkane solvents, and sulfoxide solvents; and / or, the oxidant is selected from any one or a mixture of more than one of hydrogen peroxide, sodium perborate, and urea peroxide.
6. The method according to claim 1, characterized in that, In step 2, the molar ratio of the compound, oxidant, and second base shown in formula (3) is (1-3):(1-10):(1-10); and / or, the reaction temperature is –100℃ to 60℃; and / or, the reaction time is 0.5 to 12h.
7. An α-amino acid compound, characterized in that, Its structure is as follows: in, R 2 For alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, R 3 For hydrogen, alkyl, aryl, R 4 It can be alkyl or aryl.
8. The α-amino acid compound according to claim 7, characterized in that, The α-amino acid compounds include compounds represented by the following formula:
9. The method according to any one of claims 1-7, or the α-amino acid compound according to claim 8, in large-scale industrial production, efficient preparation of chiral α-amino acid compounds, highly stereoselective preparation of chiral α-amino acid compounds, synthesis of α-natural and non-natural amino acid compounds, reduction of synthesis costs, improvement of reaction sustainability and environmental friendliness, and application in drug synthesis.
10. An intermediate, characterized in that, Its structure is as follows: in, R 1 It is alkyl, aryl, or hydrogen; R 2 For alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl; R 3 It is hydrogen, alkyl, or aryl; R 4 It can be alkyl or aryl.
